SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW0113 ...
(RTTNews) - Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, said its Adalimumab Injection 9MW0113, marketed as JUNMAIKANG in China, has ...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its adalimumab injection 9MW0113 (Marketed as Junmaikang in China) has been granted ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
Going into 2026, biotech company Ladder Bio is embracing a new identity.
Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in infrequent-dosing biologics. See more.
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality ...
Zacks Investment Research on MSN
ANIP vs. TEVA: Which drug stock is the better buy right now?
Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...
AbbVie has signed a landmark US administration deal, pledging $100bn in domestic manufacturing and R&D investment in exchange ...
AbbVie is the 16th of 17 pharmaceutical giants to agree a cut-price medicines deal in the US, adding a US$100bn investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback